Form 8-K Zivo Bioscience, Inc. For: Nov 12

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): November 12, 2018

 

ZIVO BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

 

Nevada		000-30415		87-0699977
(State or other jurisdiction		(Commission		(IRS Employer Identification No.)
of incorporation)		File Number)

 

2804 Orchard Lake Road, Suite 202, Keego Harbor, Michigan 48320

(Address of principal executive offices and zip code)

 

(248) 452-9866

(Registrant's telephone number including area code)

 

Not applicable

(Registrant's former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company [   ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [   ]

 

 

---

1

---

 

 

Item 8.01 Other Events.

 

On November 12, 2018, Zivo Bioscience, Inc. (“Zivo”) issued a press release to announce that it obtained GRAS (Generally Recognized As Safe) status, having completed a two year safety and toxicity effort, as reviewed by an independent scientific panel, which accepted the findings of multiple studies and tests conducted by contract research organizations and independent laboratories engaged by ZIVO. This development allows ZIVO to immediately begin marketing its algal biomass as a food ingredient in the United States.  A copy of the related press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibit is filed as part of this report:

 

Exhibit 99.1 – Press Release, dated November 12, 2018.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	ZIVO BIOSCIENCE, INC.
Dated: November 14, 2018	By:	/s/ Philip M. RICE II
		Name: Philip M. Rice, II
		Title: Chief Financial Officer

 

---

2

 

Exhibit 99.1

 

ZIVO CLAIMS GRAS STATUS FOR ITS PROPRIETARY ALGAL BIOMASS, ALLOWING IMMEDIATE MARKETING OF ITS PREMIERE PRODUCT AS A HUMAN FOOD INGREDIENT

 

KEEGO HARBOR, Mich., (November 12, 2018) -- ZIVO Bioscience, Inc. (OTCMKTS: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that it has received notice from an independent scientific review panel that ZIVO has satisfied the safety and process requirements to affirm GRAS status for its proprietary Kalgae™ branded dried algal biomass. GRAS refers to FDA designation Generally Recognized As Safe and allows the Company to market its product as an ingredient in a defined range of foods and beverages.

 

Initially, the Company will target vegan and functional food & beverage categories, ranging from veggie smoothies to snack bars intended for human consumption. GRAS status allows manufacturers and marketers to integrate the Kalgae™ ingredient into food processing lines and products, and to include its nutritional information on product labels. In turn, the Company has embarked on a comprehensive plan to build a global supply chain and furnish its algal biomass product on a large scale, while maintaining the highest quality and safety standards.

 

A parallel process to certify the Kalgae™ algal biomass as a phytogenic feed ingredient for poultry nutrition commenced in April 2018 and is expected to wind up in the first quarter of 2019, once again allowing the Company to immediately begin marketing its premiere product in this fast-growing $780 million segment of the poultry feed industry. Feed trials and customer demonstrations will likely precede the official launch date, to accommodate lead times for delivery of the product to prospective customers.

 

These developments provide the Company its first opportunity to generate revenue from sales of its premiere product in the US, to be followed by subsequent planned entries into European and Asian markets.

 

About ZIVO Bioscience, Inc.

 

ZIVO Bioscience, Inc. (OTCQB: ZIVO) is a Michigan-based biotech company engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.

 

Safe Harbor Statement

 

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

 

Contact:

Investor Relations
(248) 452 9866 ext 150
ZIVO Bioscience, Inc.    
[email protected]

 

Source: Zivo Bioscience, Inc.

Released November 12, 2018